(Redirected from
EP Hormone)
 | |
Estradiol dipropionate (top) and
hydroxyprogesterone caproate (bottom) | |
| Combination of | |
|---|---|
| Estradiol dipropionate | Estrogen |
| Hydroxyprogesterone caproate | Progestogen |
| Clinical data | |
| Trade names | EP Hormone Depot |
| Other names | EDP/OHPC |
|
Routes of administration | Intramuscular injection |
| ATC code | |
| Identifiers | |
| PubChem SID | |
| KEGG | |
Estradiol dipropionate/hydroxyprogesterone caproate (EDP/OHPC), sold under the brand name EP Hormone Depot, is a combined estrogen– progestogen medication which is used in Japan. [1] [2] [3] [4] [5] [6] [7] [8] It is manufactured by Teikoku Zoki Pharmaceutical Co., Tokyo and contains 1 mg/mL estradiol dipropionate and 50 mg/mL hydroxyprogesterone caproate. [2] [3] [4] [5] [6] [7] [8]
See also
- Estradiol benzoate/hydroxyprogesterone caproate
- Estradiol valerate/hydroxyprogesterone caproate
- List of combined sex-hormonal preparations
References
-
^
"Archived copy". Archived from
the original on 2019-04-07. Retrieved 2018-09-17.
{{ cite web}}: CS1 maint: archived copy as title ( link) - ^ a b Kawamura I, Mizota T, Lacey E, Tanaka Y, Manda T, Shimomura K, Kohsaka M (September 1993). "The estrogenic and antiestrogenic activities of droloxifene in human breast cancers". Jpn. J. Pharmacol. 63 (1): 27–34. doi: 10.1254/jjp.63.27. PMID 8271528.
- ^ a b Asanuma F, Yamada Y, Kawamura E, Lee K, Kobayashi H, Yamada T, Suzuki T, Kubota T (1998). "Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27". Folia Microbiol. (Praha). 43 (5): 473–4. doi: 10.1007/BF02820793. PMID 9821299. S2CID 22732235.
- ^
a
b Noguchi M, Tajiri K, Taniya T, Kumaki T, Ashikari A, Miyazaki I (1990). "Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7)". Oncology. 47 (1): 19–24.
doi:
10.1159/000226779.
PMID
2137212.
After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week.
- ^ a b Kubota T, Oka S, Utsumi T, Inoue S, Kuzuoka M, Suto A, Arisawa Y, Ishibiki K, Abe O (July 1989). "Human breast carcinoma (ZR-75-1) serially transplanted into nude mice--with reference to estradiol dependency and sensitivity to tamoxifen". Jpn J Surg. 19 (4): 446–51. doi: 10.1007/BF02471626. PMID 2810959. S2CID 23267652.
- ^ a b Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M (March 1994). "FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity". J. Antibiot. 47 (3): 301–10. doi: 10.7164/antibiotics.47.301. PMID 7513682.
- ^ a b Hori Y, Abe Y, Nishimura M, Goto T, Okuhara M, Kohsaka M (July 1993). "R1128 substances, novel non-steroidal estrogen-receptor antagonists produced by a Streptomyces. III. Pharmacological properties and antitumor activities". J. Antibiot. 46 (7): 1069–75. doi: 10.7164/antibiotics.46.1055. PMID 8360101.
- ^ a b Noguchi M, Koyasaki N, Miyazaki I, Mizukami Y (November 1991). "Effects of hormones on tumor growth and immunoreactive insulin-like growth factor-1 of estrogen receptor-positive human breast cancer (MCF-7) transplanted in nude mice". Jpn. J. Cancer Res. 82 (11): 1199–202. doi: 10.1111/j.1349-7006.1991.tb01780.x. PMC 5918318. PMID 1752778.
(Redirected from
EP Hormone)
|
| |
|
Estradiol dipropionate (top) and
hydroxyprogesterone caproate (bottom) | |
| Combination of | |
|---|---|
| Estradiol dipropionate | Estrogen |
| Hydroxyprogesterone caproate | Progestogen |
| Clinical data | |
| Trade names | EP Hormone Depot |
| Other names | EDP/OHPC |
|
Routes of administration | Intramuscular injection |
| ATC code | |
| Identifiers | |
| PubChem SID | |
| KEGG | |
Estradiol dipropionate/hydroxyprogesterone caproate (EDP/OHPC), sold under the brand name EP Hormone Depot, is a combined estrogen– progestogen medication which is used in Japan. [1] [2] [3] [4] [5] [6] [7] [8] It is manufactured by Teikoku Zoki Pharmaceutical Co., Tokyo and contains 1 mg/mL estradiol dipropionate and 50 mg/mL hydroxyprogesterone caproate. [2] [3] [4] [5] [6] [7] [8]
See also
- Estradiol benzoate/hydroxyprogesterone caproate
- Estradiol valerate/hydroxyprogesterone caproate
- List of combined sex-hormonal preparations
References
-
^
"Archived copy". Archived from
the original on 2019-04-07. Retrieved 2018-09-17.
{{ cite web}}: CS1 maint: archived copy as title ( link) - ^ a b Kawamura I, Mizota T, Lacey E, Tanaka Y, Manda T, Shimomura K, Kohsaka M (September 1993). "The estrogenic and antiestrogenic activities of droloxifene in human breast cancers". Jpn. J. Pharmacol. 63 (1): 27–34. doi: 10.1254/jjp.63.27. PMID 8271528.
- ^ a b Asanuma F, Yamada Y, Kawamura E, Lee K, Kobayashi H, Yamada T, Suzuki T, Kubota T (1998). "Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27". Folia Microbiol. (Praha). 43 (5): 473–4. doi: 10.1007/BF02820793. PMID 9821299. S2CID 22732235.
- ^
a
b Noguchi M, Tajiri K, Taniya T, Kumaki T, Ashikari A, Miyazaki I (1990). "Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7)". Oncology. 47 (1): 19–24.
doi:
10.1159/000226779.
PMID
2137212.
After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week.
- ^ a b Kubota T, Oka S, Utsumi T, Inoue S, Kuzuoka M, Suto A, Arisawa Y, Ishibiki K, Abe O (July 1989). "Human breast carcinoma (ZR-75-1) serially transplanted into nude mice--with reference to estradiol dependency and sensitivity to tamoxifen". Jpn J Surg. 19 (4): 446–51. doi: 10.1007/BF02471626. PMID 2810959. S2CID 23267652.
- ^ a b Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M (March 1994). "FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity". J. Antibiot. 47 (3): 301–10. doi: 10.7164/antibiotics.47.301. PMID 7513682.
- ^ a b Hori Y, Abe Y, Nishimura M, Goto T, Okuhara M, Kohsaka M (July 1993). "R1128 substances, novel non-steroidal estrogen-receptor antagonists produced by a Streptomyces. III. Pharmacological properties and antitumor activities". J. Antibiot. 46 (7): 1069–75. doi: 10.7164/antibiotics.46.1055. PMID 8360101.
- ^ a b Noguchi M, Koyasaki N, Miyazaki I, Mizukami Y (November 1991). "Effects of hormones on tumor growth and immunoreactive insulin-like growth factor-1 of estrogen receptor-positive human breast cancer (MCF-7) transplanted in nude mice". Jpn. J. Cancer Res. 82 (11): 1199–202. doi: 10.1111/j.1349-7006.1991.tb01780.x. PMC 5918318. PMID 1752778.